Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial.
cam.issuedOnline | 2021-11-23 | |
dc.contributor.author | Bellingan, G | |
dc.contributor.author | Jacono, F | |
dc.contributor.author | Bannard-Smith, J | |
dc.contributor.author | Brealey, D | |
dc.contributor.author | Meyer, N | |
dc.contributor.author | Thickett, D | |
dc.contributor.author | Young, D | |
dc.contributor.author | Bentley, A | |
dc.contributor.author | McVerry, BJ | |
dc.contributor.author | Wunderink, RG | |
dc.contributor.author | Doerschug, KC | |
dc.contributor.author | Summers, C | |
dc.contributor.author | Rojas, M | |
dc.contributor.author | Ting, A | |
dc.contributor.author | Jenkins, ED | |
dc.contributor.orcid | Bellingan, G [0000-0003-4193-4689] | |
dc.contributor.orcid | Ting, A [0000-0002-5058-9576] | |
dc.date.accessioned | 2022-01-10T12:46:37Z | |
dc.date.available | 2022-01-10T12:46:37Z | |
dc.date.issued | 2022-01 | |
dc.date.submitted | 2021-08-17 | |
dc.date.updated | 2022-01-10T12:46:36Z | |
dc.description.abstract | PURPOSE: Bone marrow-derived, allogeneic, multipotent adult progenitor cells demonstrated safety and efficacy in preclinical models of acute respiratory distress syndrome (ARDS). METHODS: This phase 1/2 trial evaluated the safety and tolerability of intravenous multipotent adult progenitor cells in patients with moderate-to-severe ARDS in 12 UK and USA centres. Cohorts 1 and 2 were open-label, evaluating acute safety in three subjects receiving 300 or 900 million cells, respectively. Cohort 3 was a randomised, double-blind, placebo-controlled parallel trial infusing 900 million cells (n = 20) or placebo (n = 10) within 96 h of ARDS diagnosis. Primary outcomes were safety and tolerability. Secondary endpoints included clinical outcomes, quality of life (QoL) and plasma biomarkers. RESULTS: No allergic or serious adverse reactions were associated with cell therapy in any cohort. At baseline, the cohort 3 cell group had less severe hypoxia. For cohort 3, 28-day mortality was 25% for cell vs. 45% for placebo recipients. Median 28-day free from intensive care unit (ICU) and ventilator-free days in the cell vs. placebo group were 12.5 (IQR 0,18.5) vs. 4.5 (IQR 0,16.8) and 18.5 (IQR 0,22) vs. 6.5 (IQR 0,18.3), respectively. A prospectively defined severe ARDS subpopulation (PaO2/FiO2 < 150 mmHg (20 kPa); n = 16) showed similar trends in mortality, ICU-free days and ventilator-free days favouring cell therapy. Cell recipients showed greater recovery of QoL through Day 365. CONCLUSIONS: Multipotent adult progenitor cells were safe and well tolerated in ARDS. The clinical outcomes warrant larger trials to evaluate the therapeutic efficacy and optimal patient population. | |
dc.description.sponsorship | National Institutes of Health, Innovate UK, and Athersys, Inc | |
dc.identifier.doi | 10.17863/CAM.79951 | |
dc.identifier.eissn | 1432-1238 | |
dc.identifier.issn | 0342-4642 | |
dc.identifier.other | s00134-021-06570-4 | |
dc.identifier.other | 6570 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/332501 | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.publisher.url | http://dx.doi.org/10.1007/s00134-021-06570-4 | |
dc.subject | Acute respiratory distress syndrome (ARDS) | |
dc.subject | Multipotent adult progenitor cells (MAPC) | |
dc.subject | Stem cells | |
dc.subject | Adult | |
dc.subject | Double-Blind Method | |
dc.subject | Humans | |
dc.subject | Intensive Care Units | |
dc.subject | Quality of Life | |
dc.subject | Respiratory Distress Syndrome | |
dc.subject | Stem Cells | |
dc.subject | Treatment Outcome | |
dc.title | Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. | |
dc.type | Article | |
dcterms.dateAccepted | 2021-10-28 | |
prism.endingPage | 44 | |
prism.issueIdentifier | 1 | |
prism.publicationName | Intensive Care Med | |
prism.startingPage | 36 | |
prism.volume | 48 | |
pubs.funder-project-id | National Institute on Alcohol Abuse and Alcoholism (R42AA024003) | |
pubs.funder-project-id | Innovate UK (102165) | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1007/s00134-021-06570-4 |
Files
Original bundle
1 - 5 of 6
No Thumbnail Available
- Name:
- 134_2021_Article_6570_nlm.xml
- Size:
- 81.5 KB
- Format:
- Extensible Markup Language
- Description:
- Bibliographic metadata
- Licence
- http://creativecommons.org/licenses/by-nc/4.0/
Loading...
- Name:
- 134_2021_6570_MOESM2_ESM.pdf
- Size:
- 329.47 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- http://creativecommons.org/licenses/by-nc/4.0/
Loading...
- Name:
- 134_2021_6570_MOESM1_ESM.pdf
- Size:
- 229.74 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- http://creativecommons.org/licenses/by-nc/4.0/
No Thumbnail Available
- Name:
- additional-files.zip
- Size:
- 113.04 KB
- Format:
- ZIP file
- Description:
- Supporting information
- Licence
- http://creativecommons.org/licenses/by-nc/4.0/
Loading...
- Name:
- 134_2021_Article_6570.pdf
- Size:
- 1.07 MB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- http://creativecommons.org/licenses/by-nc/4.0/